Drug-drug interactions between COVID-19 therapeutics and psychotropic medications.

Understanding and managing potential DDIs between COVID-19 and psychotropic medications is paramount to ensuring safe and effective treatment of patients with COVID-19 and mental illness. Awareness of the diverse spectrum of DDIs, vigilant monitoring, and judicious dose modifications, while choosing pharmacotherapeutic options with low risk of interaction whenever possible, are necessary. Ongoing and future investigations should continue to review and assess the dynamic landscape of COVID-19 therapeutic modalities and carefully elucidate their interactions with psychotropic medications. This ongoing commitment to research is critical to providing clinicians with contemporaneous insights, thereby enabling them to skillfully navigate the complexities of managing individuals struggling with mental health disorders in the context of the COVID-19 pandemic.